# Progress towards OV elimination and research update in Cameroon

- Dr Benjamin Didier Biholong, MD, MPH.
  - NOCP coordinator, MoH Cameroon
- Henri Claude Moungui, MPH, MRes.
  - Program Officer, NOCP, MoH Cameroon.

## OV control background in Cameroun

- 189 health districts
  - ◆ 113 OV hyper/meso endemic (under MDA, all with at least 12 years)
  - ◆ 76 OV hypo endemic districts
- Control strategy:
  - ◆ MDA following CDTI strategy

#### OV program/researchers partnering in Cameroon

- 4 implementing NGDOs:
  - Helen Keller International,
  - International Eye Foundation,
  - PersPectives,
  - Sightsavers
- Main research centers implementing program surveys (mapping, coverage survey, epi. Surveys)
  - ◆ CRFilMT (Yaounde)
  - ◆ REFOTDE (Buea)
  - ◆ Independant/academic researchers

# Challenges to OV elimination in Cameroon

- Co-endemicity to loiasis (in 95 districts, 31 hypo untreated, 64 hyper/meso under MDA)
- Systemic non-compliance
- Still hyper-endemic areas after 15 years MDA (hotspots)
- Lack of funding support for OV epi assessments (low priority of donors, research needed on OV epi assessment tools/techniques)

#### OV epidemiological assessments

■ Under WHO/APOC, 6 projects assessed

(max values REMO → Epi eval)

- ♦ North : 6.0 88.7 → 0.0 17.0
- ♦ Adamaoua : 5.6-70.0 → 0.0 6.7
- ◆ SW: 39.21 78.00 → 45.45
- ♦ Centre: 10.0 83.3 → 51.4 71.4
- ♦ Littoral: 43.7 66.7 → **50.5**
- West:  $60.0 100.0 \rightarrow 1.7 45.8$
- 4 projects never assessed in Far North, East,
  South, NW

## Prospects to elimination

- Continue CDTI
- Alternative strategies:
  - ◆ 2X year CDTI
  - ◆ Doxycycline 5-week regimen
  - ◆ Test and Not Treat in loiasis coendemic areas
  - Vector control
- National OV Elimination Committee (1st meeting in Jan 2018)
  - Need for re-mapping/impact OV assessments in hypo and some hyper/meso areas;
  - ◆ Integrate and analyze historical data at health area/community level;
  - Discuss future research with the committee

# Ongoing research projects on OV in Cameroon

- Test and Not Treat by CRFilMT
  - ◆ Test for L.loa mf load first. People with mf loads above 20,000mf/ml excluded from IVM intake;
  - ◆ IVM for eligible individuals;
  - ◆ Albendazole for excluded for high loa individuals
- Massangam project
  - ◆ Test and Treat (OV first) + 5 weeks doxycycline;
  - ◆ 2X year IVM;
  - Ground larviciding;

# Ongoing research projects on OV in Cameroon

- Countdown (alternative strategies in Meme river)
  - One round doxycycline in hostspots
  - Ground larviciding

# Last but not least!

Clinical research is not all!

- Think about social science research:
  - ◆ Implementation problems
  - ◆ Health economics questions
  - SBCC questions

Strengthening program staff capacity on OV diagnostic tests

Thank you